OLX-07010 is under clinical development by Oligomerix and currently in Phase I for Progressive Supranuclear Palsy. According to GlobalData, Phase I drugs for Progressive Supranuclear Palsy does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the OLX-07010 LoA Report. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
OLX-07010 overview
OLX-07010 inhibitor is under development for the treatment of Alzheimer's disease, rare tauopathies like supranuclear palsy and frontotemporal dementia, mild cognitive impairment. It is administered through oral route. The drug candidate is a small molecule acts by targeting tau oligomer formation.
Oligomerix overview
Oligomerix is a biotech company that develops proprietary platform technology for drug discovery and biomarker development for central nervous system (CNS) disorders focused on AD, and use that platform to discover unique, drug-like small molecules. Oligomerix is headquartered in White Plains, New York, the US.
For a complete picture of OLX-07010’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
